Ashland INC 10-Q quarterly reports

Ashland Inc. reported a net income of $16 million for the third quarter of fiscal year 2026, a significant improvement from the prior year's net loss.

Ashland Inc. reported a slight increase in Q1 2026 sales, but net income declined year-over-year, impacted by global trade uncertainties, geopolitical conflicts, and operational challenges.

Ashland Inc. reported a significantly reduced net loss for Q1 FY26, driven by the absence of prior year's impairment charges, but narrowed its full-year Adjusted EBITDA guidance due to temporary operational disruptions.

Ashland Inc. reported a substantial net loss of $742 million for the third quarter of fiscal 2025, primarily driven by a $706 million non-cash goodwill impairment charge, and updated its full-year fiscal 2025 sales and Adjusted EBITDA guidance downwards.

Ashland Inc. reports a decrease in sales for Q2 2025, but manages to improve profitability through cost reduction initiatives and portfolio optimization.

Ashland Inc. reported a net loss for the first quarter of fiscal year 2025, primarily due to a significant impairment charge related to the planned sale of its Avoca business.

Ashland Inc. reported a net income of $6 million for the third quarter of 2024, impacted by a significant impairment charge related to the divestiture of its Nutraceuticals business, while also showing some positive trends in other segments.

Ashland Inc. reported a net income of $120 million for the second quarter of 2024, showing a year-over-year increase, but faced challenges from unfavorable pricing and higher expenses.

Ashland Inc. reported a decrease in sales and operating income for the first quarter of fiscal year 2024, impacted by lower volumes and restructuring activities, while also highlighting a new stock repurchase program and a one-time stock grant to the CEO.